


# FLAVOUR KLINIKKEN


HOLSTEBRO - DENMARK



## Sensoriske forandringer som senfølge hos COVID-19 patienter

Dansk Selskab for Klinisk Ernæring  
Årsmøde 2021  
07.05.2021






# Sensoriske senfølger ved COVID-19

## Relevans i DSKE-regi

- Sensoriske tab er relevante for ernæring og udarbejdelsen af ernæringsplaner for patienter
- God ernæringsvejledning kræver en individuel tilgang
- COVID-19 kan forårsage meget varierende sensoriske senfølger




# Sensoriske senfølger ved COVID-19

## Sansetab

"Det er bedre at have elsket og mistet end slet ikke at have elsket."\*

- **Alfred Lord Tennyson (1809-1892)**


\*Det gælder dog ikke for patienter med fx lugtetab, der ofte mister kærligheden til mad og er meget mere påvirkede af sansetabet end patienter, der er født uden lugtesans



# Lugtetab

## Er det overhovedet relevant?


- Nedsat nydelse af mad (Største indvirkning på livskvalitet)
- Manglende registrering af fare (mad, røg etc.)
- Problemer med arbejde (sygeplejeske, pædagog, kok, politi etc.)
- Socialt hæmmende (kropslugte, partner, middage etc.)
- Øget risiko for angst og depression (lugtetab  $\leftrightarrow$  depression)
- Mest præcise symptom som markør for COVID-19
- Hyppigt vedvarende sansetab efter COVID-19



# Lugtetab



## Hyppighed ved COVID-19


- Subjektivt lugtetab (tidligt):
  - 64% med lugtetab (yngre, mildt forløb, n=202) (Spinato, 2020)
  - 65% med lugtetab (n=6.452) (Menni, 2020)
- Testverificeret lugtetab (tidligt):
  - Både lugte- og smagstab (Haldrup, 2020)
  - 98% med lugtetab (indlagte med COVID-19, n=60) (Moein, 2020)



# Lugte- og smagstab


## Varighed af COVID-19-sansetab






# Lugte- og smagstab

## Varighed af COVID-19-sansetab






# Lugtetab

## Hyppighed (præ-COVID-19)

### Lugteforstyrrelser

- Subjektivt:
  - 4,5% (stigende med alder) (Lee, 2013)
  - 10,6% indenfor de sidste 12 måneder (Bhatt, 2015)
  - 23% har oplevet lugtetab i voksenlivet (Rawal, 2016)
- Testet:
  - 4,7% Anosmi og 15% hyposmi (Landis, 2004)
  - 3,6% Anosmi og 21,6% hyposmi (Vennemann, 2008)
- Nogle sygdomme giver øget forekomst (fx diabetes, nyresygdom)



# Lugtetab

## Årsager

### **Sino-nasal påvirkning**

Rhino-sinuitis  
(Akut/kronisk, med/uden polypper)  
Allergisk rhinitis  
Øvrig slimhindehævelse/påvirkning  
(fx graviditet)  
Nedsat passage (fx næsefraktur)

### **Postinfektiøst**

Øvre eller nedre luftveje  
Direkte nerveskade (apoptose)  
Fortsat hævelse/irritation

### **Posttraumatisk**

Nedsat passage  
Overrivning af filae olfactoriae  
Skade på cortex  
Blodansamling ved bulbus olfactorius

### **Central nervepåvirkning**

Apoplexi eller tumor  
(fx sulcus olfactorius, piriform cortex,  
temporallap, amygdala, limbisk system)  
Neurologisk sygdom (fx MS, ALS)  
Neurodegenerativ sygdom (fx PD, ALZ)

### **Iatrogen**

Lokal kirurgi (fx FESS, lokal analgesi  
(Moffats), hjernekirurgi)  
Generel anæstesi

### **Kongenit**

Syndromer (fx Kallmann syndrom,  
Klinefelter syndrom, CHARGE syndrom)  
Mange øvrige årsager (fx CMV)


### **Bivirkninger og nerveskader**

Stråleterapi  
Kemoterapi  
Medicin (Fx antibiotika, antihypertensiv)  
Mad eller miljøtoksiner  
Rygning

### **Aldersrelateret**


### **Psykologisk / psykiatrisk**


### **Idiopatisk**



# Lugtetab


## Årsager (primærsektor)






# Lugtetab


## Årsager (Flavour Klinikker)



Danmark (Holstebro)



Tyskland (Køln)



# Lugtetab


## Postinfektiøst lugtetab

### Tidligere

- Blandede virale infektioner
- Isoleret lugtetab
- Midaldrende patienter (gns. 62 år)

### 2020-21


- SARS-CoV2 dominerer
- Lugte- **og smagstab**
- Yngre patienter (gns. 40 år)



# Sansetab og COVID-19

## Ikke blot en reduktion af sansning

- Introduktion til termer
- Hvorfor er især lugtesansen ramt?
- Et multisensorisk problem
- Hvilke sanser er påvirkede?
- Mad og kostændringer ved COVID-19 sansetab




# Lugtetaab Overblik


Stimuli




Sansning





Perception






# Lugtetab



## Aktivering af receptorer






# Lugtetab


## Olfaktoriske receptorer






# Lugtatab

## COVID-19





# Lugtatab COVID-19

nature  
medicine

BRIEF COMMUNICATION

<https://doi.org/10.1038/s41591-020-0868-6>



## SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Waradon Sungnak<sup>1</sup>✉, Ni Huang<sup>1</sup>, Christophe Bécavin<sup>2</sup>, Marijn Berg<sup>3,4</sup>, Rachel Queen<sup>5</sup>, Monika Litvinukova<sup>1,6</sup>, Carlos Talavera-López<sup>1</sup>, Henrike Maatz<sup>6</sup>, Daniel Reichart<sup>7</sup>, Fotios Sampaziotis<sup>8,9,10</sup>, Kaylee B. Worlock<sup>11</sup>, Masahiro Yoshida<sup>11</sup>, Josephine L. Barnes<sup>11</sup> and HCA Lung Biological Network<sup>\*</sup>✉


**We investigated SARS-CoV-2 potential tropism by surveying expression of viral entry-associated genes in single-cell RNA-sequencing data from multiple tissues from healthy human donors. We co-detected these transcripts in specific respiratory, corneal and intestinal epithelial cells, potentially explaining the high efficiency of SARS-CoV-2 transmission. These genes are co-expressed in nasal epithelial cells with genes involved in innate immunity, highlighting the cells' potential role in initial viral infection, spread and clearance. The study offers a useful resource for further lines of inquiry with valuable clinical samples from COVID-19 patients and we provide our data in a comprehensive, open and user-friendly fashion at [www.covid19cellatlas.org](http://www.covid19cellatlas.org).**

The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)<sup>1</sup>. Detection of the virus was first reported in Wuhan<sup>2</sup>, China and has since spread worldwide, emerging as a global pandemic<sup>3</sup>.

associated with SARS-CoV-2 pathogenesis at cellular resolution, using single-cell RNA sequencing (scRNA-seq) datasets from healthy donors generated by the Human Cell Atlas consortium and other resources to inform and prioritize the use of precious, limited clinical material that is becoming available from COVID-19 patients.

We investigated gene expression of *ACE2* in multiple scRNA-seq datasets from different tissues, including those of the respiratory tree, cornea, retina, esophagus, ileum, colon, heart, skeletal muscle, spleen, liver, placenta/decidua, kidney, testis, pancreas, prostate gland, brain, skin and fetal tissues. We note that studies may lack specific cell types due to their sparsity, the challenges associated with isolation or analysis methodology. Moreover, expression may be under-detected due to technical dropout effects. Thus, while positive (presence) results are highly reliable, absence should be interpreted with care.

*ACE2* expression was generally low in all analyzed datasets. Consistently with independent studies<sup>10,11</sup>, *ACE2* was expressed in



# Lugtatab COVID-19

nature  
medicine

BRIEF COMMUNICATION

<https://doi.org/10.1038/s41591-020-0916-2>



## Real-time tracking of self-reported symptoms to predict potential COVID-19


Cristina Menni <sup>1,7</sup> , Ana M. Valdes <sup>1,2,7</sup>, Maxim B. Freidin <sup>1</sup>, Carole H. Sudre<sup>3</sup>, Long H. Nguyen <sup>4</sup>, David A. Drew <sup>4</sup>, Sajaysurya Ganesh <sup>5</sup>, Thomas Varsavsky<sup>3</sup>, M. Jorge Cardoso<sup>3</sup>, Julia S. El-Sayed Moustafa <sup>1</sup>, Alessia Visconti<sup>1</sup>, Pirro Hysi<sup>1</sup>, Ruth C. E. Bowyer <sup>1</sup>, Massimo Mangino <sup>1,6</sup>, Mario Falchi<sup>1</sup>, Jonathan Wolf<sup>5</sup>, Sebastien Ourselin<sup>3</sup>, Andrew T. Chan<sup>4</sup>, Claire J. Steves<sup>1,8</sup> and Tim D. Spector <sup>1,8</sup> 

**A total of 2,618,862 participants reported their potential symptoms of COVID-19 on a smartphone-based app. Among the 18,401 who had undergone a SARS-CoV-2 test, the proportion of participants who reported loss of smell and taste was higher in those with a positive test result (4,668 of 7,178 individuals; 65.03%) than in those with a negative test result (2,436 of 11,223 participants; 21.71%) (odds ratio = 6.74; 95% confidence interval = 6.31–7.21). A model combining symptoms to predict probable infection was applied to the data from all app users who reported symptoms (805,753) and predicted that 140,312 (17.42%) participants are likely to have COVID-19.**

COVID-19 is an acute respiratory illness caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since its outbreak in China in December 2019,

als and tracks in real time how the disease progresses by recording self-reported health information on a daily basis, including symptoms, hospitalization, reverse-transcription PCR (RT-PCR) test outcomes, demographic information and pre-existing medical conditions.

Between 24 March and 21 April 2020, 2,450,569 UK and 168,293 US individuals reported symptoms through the smartphone app. Of the 2,450,569 participants in the United Kingdom, 789,083 (32.2%) indicated having one or more potential symptoms of COVID-19 (Table 1). In total, 15,638 UK and 2,763 US app users reported having had an RT-PCR SARS-CoV-2 test, and having received the outcome of the test. In the UK cohort, 6,452 participants reported a positive test and 9,186 participants had a negative test. In the cohort from the United Kingdom, of the 6,452 participants who tested positive for SARS-CoV-2, 4,178 (64.76%) reported loss of smell




# Lugtetab COVID-19

**Table 1 | Characteristics of the study population**


|                                             | Tested for SARS-CoV-2 |                 |                 |                 | Not tested for SARS-CoV-2 |               |
|---------------------------------------------|-----------------------|-----------------|-----------------|-----------------|---------------------------|---------------|
|                                             | United Kingdom        |                 | United States   |                 | United Kingdom            | United States |
|                                             | Tested positive       | Tested negative | Tested positive | Tested negative |                           |               |
| Number                                      | 6,452                 | 9,186           | 726             | 2,037           | 2,434,931                 | 165,530       |
| Female (%)                                  | 71.88                 | 76.40           | 78.10           | 82.28           | 64.24                     | 68.67         |
| Age (years)                                 | 41.25 (12.18)         | 41.87 (12.14)   | 44.65 (14.31)   | 47.25 (13.80)   | 43.38 (14.69)             | 53.00 (16.68) |
| BMI (kg m <sup>-2</sup> )                   | 27.34 (6.06)          | 27.04 (5.91)    | 28.04 (6.91)    | 27.71 (6.36)    | 26.39 (5.44)              | 27.08 (5.87)  |
| Answered questions on symptoms ( <i>n</i> ) | 6,452                 | 9,186           | 726             | 2,037           | 773,539                   | 32,214        |
| Loss of smell and taste (%)                 | 64.76                 | 22.68           | 67.49           | 17.33           | 9.50                      | 12.10         |
| Fatigue (%)                                 | 29.80                 | 15.56           | 23.42           | 21.50           | 8.71                      | 8.17          |
| Shortness of breath (%)                     | 15.27                 | 9.37            | 13.50           | 12.03           | 4.52                      | 3.65          |
| Fever (%)                                   | 34.34                 | 23.93           | 27.74           | 26.25           | 9.31                      | 4.78          |
| Persistent cough (%)                        | 56.73                 | 45.56           | 44.77           | 41.24           | 30.17                     | 22.25         |
| Diarrhea (%)                                | 25.95                 | 19.24           | 32.92           | 29.06           | 19.33                     | 23.26         |
| Delirium (%)                                | 17.87                 | 13.25           | 23.55           | 23.47           | 15.26                     | 16.25         |
| Skipped meals (%)                           | 42.03                 | 24.93           | 47.25           | 36.08           | 19.12                     | 21.42         |
| Abdominal pain (%)                          | 21.31                 | 18.24           | 20.94           | 21.06           | 3.70                      | 15.94         |
| Chest pain (%)                              | 42.73                 | 39.17           | 38.57           | 41.92           | 18.65                     | 24.74         |
| Hoarse voice (%)                            | 31.70                 | 25.85           | 26.86           | 25.72           | 7.86                      | 13.79         |


The results are presented as percentage values for dichotomous traits and as means and standard deviation (in parentheses) for continuous traits (age and BMI).



# Sensoriske senfølger ved COVID-19

## Et multisensorisk problem







# Sensoriske senfølger ved COVID-19

## Et multisensorisk problem

- Lugtesansen
- Smagssansen
- Trigeminal sansning





| Variable          | Clinical Assessment |       |                 |       | Lab Test        |       |                 |       |
|-------------------|---------------------|-------|-----------------|-------|-----------------|-------|-----------------|-------|
|                   | Before COVID-19     |       | During COVID-19 |       | Before COVID-19 |       | During COVID-19 |       |
|                   | Mean                | SD    | Mean            | SD    | Mean            | SD    | Mean            | SD    |
| Smell             | 90.18               | 14.92 | 11.49           | 24.24 | 90.96           | 15.71 | 9.46            | 22.33 |
| Taste             | 91.33               | 13.25 | 23.34           | 29.36 | 92.00           | 14.34 | 21.23           | 28.71 |
| Chemesthesis      | 84.96               | 18.74 | 47.48           | 32.17 | 83.72           | 22.1  | 46.68           | 32.2  |
| Nasal Obstruction | 9.83                | 18.41 | 31.67           | 32.11 | 9.35            | 17.89 | 32.67           | 31.62 |



# Lugtatab COVID-19

**B**







# Lugte- og smagstab


## Hvorfor testning?

**Subjective taste and smell dysfunction**



**Measured taste and smell dysfunction**






# Lugte- og smagstab


## Simpel testning






# Lugte- og smagstab

## Intet er helt simpelt





# Lugte- og smagstab


## Trigeminale effekter

- Tab af trigeminal sensitivitet reducerer olfaktorisk funktion <sup>1</sup>
- Trigeminal aktivering er øget på slimhindeniveau hos patienter med erhvervet anosmi – dog er de centrale signaler svagere <sup>2</sup>




CO<sup>2</sup>






# Lugte- og smagstab


## Trigeminal senfølger ved COVID-19






# Lugtetab


## Mad og kostændringer






# Lugtetab


## Mad og kostændringer






# Smagstab


## Mad og kostændringer






# Smagstab


## Mad og kostændringer






# Lugte- og smagstab


## Mad og kostændringer






# Lugte- og smagstab

## Ændringer i vægt efter COVID-19






## Vejledning til patienters madlavning

### Hyposmi/anosmi

- Krydret mad (karry, barbecue, krydderurter)
- Stimuler de øvrige sanser
  - Temperatur forskelle
  - Tekstur forskelle
  - Taktilitet
  - Trigeminal stimuli

### Parosmi

- Kolde/kølige madvarer
- Spis 'Ikke-aromatisk' mad: ris, nudler, youghurt natural, uristet brød, dampede grøntsager
- Undgå: stegt kød og anden mad med stegeskorpe, løg, hvidløg, kaffe, æg, chokolade



# Flavour Klinikken

## Vejledning til patienters madlavning



Mad med lugtetab - Introduktion



Mad med lugtetab - Smagekit



Mad med lugtetab - Tekstur



Mad med lugtetab - Taktilitet


[www.Flavourinstitute.dk](http://www.Flavourinstitute.dk)

<https://www.youtube.com/>



Mad med lugtetab - Trigeminal Smerte

 VELUX FONDEN



# Sensoriske senfølger ved COVID-19

## Hovedbudskaber

- Lugtetab er det hyppigste symptom på COVID-19, hvor smagssansen oftest også er påvirket
- De sensoriske senfølger kan være permanente, men ændres ofte kvantitativt og kvalitativt over uger til måneder
- Testning af sanserne er at foretrække - især subjektivt smagstab er usikkert
- Øvrige sanser kan også være påvirkede
- Sansetab har ofte stor indflydelse på mad og madvaner